Ono Pharmaceutical and Jorna Therapeutics Announce AI-Driven Research Pact to Develop Novel RNA Editing Medications

Ono Pharmaceutical (Japan) entered into a research collaboration agreement with Jorna Therapeutics (USA) in December 2024 to develop new RNA editing drugs13.

Jorna will design RNA editing drug sequences using its proprietary generative AI model, SkyEngine, which leverages quantum mechanics-based artificial intelligence13.

Ono gains exclusive rights to discover, develop, and commercialize drug candidates produced from Jorna's RNA designs globally13.

The agreement includes upfront payments, ongoing research funding, and milestone payments based on research progress13.

This partnership aims to accelerate drug development using RNA editing technology, with a focus on delivering new therapies for patients with unmet medical needs worldwide13.

Jorna’s approach combines large-scale amino acid sequence data and language models to engineer therapeutic proteins13.

Sources:

1. https://www.ono-pharma.com/en/news/20250421.html

3. https://www.worldpharmaceuticals.net/news/ono-pharma-jorna-therapeutics-collaborate-on-rna-editing-drugs/